Bronchiectasis - Pipeline Review, H1 2018 - Product Image

Bronchiectasis - Pipeline Review, H1 2018

  • ID: 4521327
  • Report
  • 75 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Chiesi Farmaceutici SpA
  • GlaxoSmithKline Plc
  • Grifols SA
  • Insmed Inc
  • Kamada Ltd
  • Polyphor Ltd
  • MORE
Bronchiectasis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Pipeline Review, H1 2018, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.

Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis.

Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.

Report Highlights:

This latest pipeline guide Bronchiectasis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 3 respectively.

Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Chiesi Farmaceutici SpA
  • GlaxoSmithKline Plc
  • Grifols SA
  • Insmed Inc
  • Kamada Ltd
  • Polyphor Ltd
  • MORE
Introduction

Report Coverage

Bronchiectasis - Overview

Bronchiectasis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Bronchiectasis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchiectasis - Companies Involved in Therapeutics Development

Alitair Pharmaceuticals Inc

Chiesi Farmaceutici SpA

GlaxoSmithKline Plc

Grifols SA

Insmed Inc

Kamada Ltd

Polyphor Ltd

Recipharm AB

Bronchiectasis - Drug Profiles

alpha-1 proteinase inhibitor (human) second generation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amikacin sulfate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-3150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CHF-6333 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doxofylline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erdosteine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INS-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

murepavadin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemiralisib succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchiectasis - Dormant Projects

Bronchiectasis - Discontinued Products

Bronchiectasis - Product Development Milestones

Featured News & Press Releases

Apr 05, 2018: Aradigm Announces the EMA Has Completed Its Validation of the MAA Submission

Mar 09, 2018: Aradigm Submits Marketing Authorisation Application (MAA) to EMA for EU Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis

Jan 29, 2018: Aradigm Receives Complete Response Letter from the FDA for Linhaliq NDA

Jan 11, 2018: Aradigm Reports Results of FDA Advisory Committee Meeting on Linhaliq

Dec 01, 2017: Aradigm Announces FDA Advisory Committee Meeting for Linhali

Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions

Sep 25, 2017: Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status

Sep 15, 2017: Aradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients

Sep 05, 2017: Aradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society 2017 Annual Congress

Jul 27, 2017: Aradigm Submits New Drug Application to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis

May 03, 2017: Insmed Provides Update On Phase 2 Study Of INS1

Dec 01, 2016: Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa

Oct 18, 2016: Multi-million Dollar DTRA Funding for Biodefense Research with Aradigm Inhaled Ciprofloxacins

Sep 22, 2016: Aradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients

Mar 17, 2016: Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Bronchiectasis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Bronchiectasis - Pipeline by Alitair Pharmaceuticals Inc, H1 2018

Bronchiectasis - Pipeline by Chiesi Farmaceutici SpA, H1 2018

Bronchiectasis - Pipeline by GlaxoSmithKline Plc, H1 2018

Bronchiectasis - Pipeline by Grifols SA, H1 2018

Bronchiectasis - Pipeline by Insmed Inc, H1 2018

Bronchiectasis - Pipeline by Kamada Ltd, H1 2018

Bronchiectasis - Pipeline by Polyphor Ltd, H1 2018

Bronchiectasis - Pipeline by Recipharm AB, H1 2018

Bronchiectasis - Dormant Projects, H1 2018

Bronchiectasis - Dormant Projects, H1 2018 (Contd..1), H1 2018

Bronchiectasis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Bronchiectasis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alitair Pharmaceuticals Inc
  • Chiesi Farmaceutici SpA
  • GlaxoSmithKline Plc
  • Grifols SA
  • Insmed Inc
  • Kamada Ltd
  • Polyphor Ltd
  • Recipharm AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll